hsa-miR-132-3p miREIA test

hsa-miR-132-3p is considered one of the angiogenic miRNAs. The circulating miR-132-3p showed different expression levels between mesothelioma patients and asbestos-exposed controls. Overexpressing miR-132-3p or knocking down taurine upregulated gene 1 significantly alleviated ischemia-reperfusion induced AMI (acute myocardial infarction) in vivo.
Increase of miR-132-3p expression in white blood cells of neuropathy patients has been compared to healthy controls. miR-132-3p expression was also slightly up-regulated in sural nerve biopsies from neuropathy patients suffering from neuropathic pain compared to those without pain. Levels of miR-132-3p in neurally-derived plasma extracellular vesicles showed good sensitivity and specificity to diagnose Alzheimer's disease (AD), but did not effectively separate individuals with AD and mild cognitive impairment (MCI) from controls. It was observed that miR-132-3p and miR-146a-5p expressions were significantly decreased in the serum samples of patients with Parkinson’s disease (PD) compared to those in the healthy volunteers. Moreover, the expressions of miR-132-3p and miR-146a-5p showed a dramatic decrease in severe PD patients as compared to patients with less severe PD. Both miRNAs appear be useful as promising biomarkers for early diagnosis of PD.